Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2058-7716
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells ; volume:5 ; number:1 ; day:11 ; month:3 ; year:2019 ; pages:1-11 ; date:12.2019
Cell death discovery ; 5, Heft 1 (11.3.2019), 1-11, 12.2019
- Creator
-
Jiang, Liren
Malik, Natasha
Acedo, Pilar
Zawacka-Pankau, Joanna
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41420-019-0157-7
- URN
-
urn:nbn:de:101:1-2019040421340016313421
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jiang, Liren
- Malik, Natasha
- Acedo, Pilar
- Zawacka-Pankau, Joanna
- SpringerLink (Online service)
Other Objects (12)
Evolution of the p53-MDM2 pathway
Small-Molecule Inhibitors of p53-MDM2 interactions
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
MDM2 Is Essential to Maintain the Homeostasis of Epithelial Cells by Targeting p53
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Biochemische und strukturelle Untersuchungen an Proteinen des p53-Tumorsuppressor-Netzwerks : p53, p63 und MDM2
Biochemische und strukturelle Untersuchungen an Proteinen des p53-Tumorsuppressor-Netzwerks : p53, p63 und MDM2
The p53 network in chronic lymphocytic leukemia
Targeting the p53-MDM2 and p53-MDMX interaction as a therapeutic strategy for anticancer treatment
Targeting the p53-MDM2 and p53-MDMX interaction as a therapeutic strategy for anticancer treatment
Die Rolle von E6-Onkoprotein, p53, p53 mutiert, p16, MDM2 und Galektin-3 beim Zervixkarzinom
Evolution of the p53-MDM2 pathway
Small-Molecule Inhibitors of p53-MDM2 interactions
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
MDM2 Is Essential to Maintain the Homeostasis of Epithelial Cells by Targeting p53
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Biochemische und strukturelle Untersuchungen an Proteinen des p53-Tumorsuppressor-Netzwerks : p53, p63 und MDM2
Biochemische und strukturelle Untersuchungen an Proteinen des p53-Tumorsuppressor-Netzwerks : p53, p63 und MDM2
The p53 network in chronic lymphocytic leukemia
Targeting the p53-MDM2 and p53-MDMX interaction as a therapeutic strategy for anticancer treatment
Targeting the p53-MDM2 and p53-MDMX interaction as a therapeutic strategy for anticancer treatment
Die Rolle von E6-Onkoprotein, p53, p53 mutiert, p16, MDM2 und Galektin-3 beim Zervixkarzinom
Evolution of the p53-MDM2 pathway
Small-Molecule Inhibitors of p53-MDM2 interactions
NAT 10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2
MDM2 Is Essential to Maintain the Homeostasis of Epithelial Cells by Targeting p53
Serumantikörper gegen die Proteine p53, mdm2 und p21-waf1 und Nachweis der Proteine p53 und mdm2 in menschlichen Tumorgeweben
CDK4 inhibition diminishes p53 activation by MDM2 antagonists
Biochemische und strukturelle Untersuchungen an Proteinen des p53-Tumorsuppressor-Netzwerks : p53, p63 und MDM2
Biochemische und strukturelle Untersuchungen an Proteinen des p53-Tumorsuppressor-Netzwerks : p53, p63 und MDM2
The p53 network in chronic lymphocytic leukemia
Targeting the p53-MDM2 and p53-MDMX interaction as a therapeutic strategy for anticancer treatment
Targeting the p53-MDM2 and p53-MDMX interaction as a therapeutic strategy for anticancer treatment